Lifera, the Saudi Arabian-based contract manufacturer with backing from the nation’s Public Investment Fund, has partnered with manufacturer Resilience to establish a production site.
Resilience announced on Monday that it had secured a non-binding agreement to assist Lifera in designing and constructing a drug manufacturing facility in the Saudi capital of Riyadh. The site plans to produce bacterial and mRNA vaccines, large molecule drugs and monoclonal antibodies. Lifera will employ 200 workers at the site.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.